Cargando…
Time-to-treatment of diffuse large B-cell lymphoma in São Paulo
OBJECTIVE: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma, accounting for nearly 50% of the cases in the Hematology Department of the Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo and Instituto do Câncer do Estado de São Paulo. The treatme...
Autores principales: | Xavier, Flávia Dias, Levy, Debora, Pereira, Juliana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012239/ https://www.ncbi.nlm.nih.gov/pubmed/24838904 http://dx.doi.org/10.6061/clinics/2014(05)12 |
Ejemplares similares
-
The H/R FcγRIIA-131 polymorphism and survival in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: a study in a genetically mixed population
por: Levy, Débora, et al.
Publicado: (2011) -
Inhibition of VEGFR2 overcomes venetoclax-resistance in diffuse large B-cell lymphoma cells
por: Shi, Yuanfei, et al.
Publicado: (2022) -
Prevalence of non-Hodgkin lymphomas in São Paulo, Brazil
por: Gouveia, Gisele Rodrigues, et al.
Publicado: (2011) -
High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma
por: ZL, Wu, et al.
Publicado: (2011) -
Bortezomib depended on PRDM1 and TP53 to exert therapeutic effect in activated B-cell-like diffuse large B-cell lymphoma
por: Tang, Jing, et al.
Publicado: (2023)